BrainChip Research Enter into a Research Collaboration with Biotome for SARS-CoV-2 Antibody Detection
Retrieved on:
Tuesday, April 6, 2021
BrainChip Holdings Ltd (ASX: BRN), a leading provider of ultra-low power high performance artificial intelligence technology, today announced that the Brainchip Research Institute in Perth has entered into a research collaboration with precision immunology company Biotome Pty Ltd. Biotome is developing highly accurate antibody tests for infections.
Key Points:
- BrainChip Holdings Ltd (ASX: BRN), a leading provider of ultra-low power high performance artificial intelligence technology, today announced that the Brainchip Research Institute in Perth has entered into a research collaboration with precision immunology company Biotome Pty Ltd. Biotome is developing highly accurate antibody tests for infections.
- Dr. Samuel Lundin, CEO of Biotome said: We believe the precision of antibody tests for infections can be improved dramatically.
- Our partnership with Brainchip is an important step for our development of point-of-care tests that are based on patented high-precision immunological markers.
- If the project is successful we will apply the same principles to other antibody tests in our pipeline.